Reportlinker Adds Autacoids and Related Drugs: Technologies and Global Markets

NEW YORK, May 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Autacoids and Related Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0196567/Autacoids-and-Related-Drugs-Technologies-and-Global-Markets.html

THIS REPORT

An overview of autacoids, including such types as histamines and antihistamines, prostaglandins, angiotensin, leukotriens, prostanoids, lipids, nitrogen bases, reactive oxygen species, nitric oxide, and small oligopeptides

Analysis of market trends in related drugs, with data for 2008 and 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015

Breakdown of the industry structure with a focus on manufacturers and their market shares

Comprehensive company profiles and detailed patent analyses.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 2

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 3

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

Chapter-2: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY 5

SUMMARY TABLE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, THROUGH 2015 ($ BILLIONS) 6

SUMMARY FIGURE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, 2008-2015 ($ BILLIONS) 6

Chapter-3: OVERVIEW

DEFINITION 7

GENERAL CHARACTERISTICS OF AUTACOIDS 7

CLASSIFICATION OF AUTACOIDS 7

BIOGENIC AMINE 8

Histamine 8

Roles/ Functions of Histamine 9

Serotonin 10

Roles of Serotonin 10

Catecholamines 11

Functions of Catecholamine 12

POLYPEPTIDE AUTACOIDS 13

Angiotensin 14

Functions of Angiotensin 14

Kinins 15

Functions of Kinins 15

Vasoactive Intestinal Polypeptide 16

Functions of Vasoactive Intestinal Polypeptide 16

Natriuretic Peptides 17

Functions of Natriuretic Peptides 17

ENDOTHELIUM-DERIVED AUTACOIDS 18

Endothelins 18

Functions of Endothelins 19

Nitric Oxide 19

Functions of Nitric Oxide 19

LIPID-DERIVED AUTACOIDS 20

Eicosanoids 20

Functions of Eicosanoids 21

Platelet Activating Factor 22

Functions of Platelet-Activating Factor 22

Chapter-4: DRUGS RELATED TO AUTACOIDS

FIGURE 1 CLASSIFICATION OF DRUGS RELATED TO AUTACOIDS 23

BIOGENIC AMINES 24

HISTAMINE DRUGS 24

H1 Receptor Antagonists 24

TABLE 1 H1 RECEPTOR ANATAGONISTS 25

H2 Antagonists 26

TABLE 2 H2 RECEPTOR ANATAGONISTS 26

H3 and H4 Receptor Antagonists 26

SEROTONIN DRUGS 27

Serotonin-Norepinephrine Reuptake Inhibitors 27

TABLE 3 SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS 28

Selective Serotonin Reuptake Inhibitors (SSRIs) 28

TABLE 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS 29

Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors 29

Serotonin Receptor Agonists 30

TABLE 5 SEROTONIN RECEPTOR AGONISTS 30

Serotonin Receptor Antagonists 30

TABLE 6 SEROTONIN RECEPTOR ANTAGONISTS 31

CATECHOLAMINES 31

Directly Acting Sympathomimetic Drugs 32

TABLE 7 DIRECTLY ACTING SYMPATHOMIMETIC DRUGS 32

TABLE 7 (CONTINUED) 33

Indirectly Acting Sympathomimetic Drugs 34

TABLE 8 INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS 34

Adrenolytics 35

TABLE 9 ADRENOLYTICS 35

Dopaminergic Antagonists/Dopamine Receptor Antagonists 36

TABLE 10 DOPAMINE ANTAGONISTS 36

POLYPEPTIDE AUTACOIDS 37

ANGIOTENSIN DRUGS 37

Angiotensin II Receptor Antagonists 37

TABLE 11 ANGIOTENSIN II RECEPTOR ANTAGONISTS 38

Angiotensin-Converting Enzymes (ACE) Inhibitors 38

TABLE 12 ANGIOTENSIN CONVERTING ENZYME INHIBITORS 38

KININS 39

DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 39

TABLE 13 DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 40

DRUGS RELATED TO ENDOTHELIUM-DERIVED AUTACOIDS 40

ENDOTHELIN RECEPTOR ANTAGONISTS 40

TABLE 14 ENDOTHELIN RECEPTOR ANTAGONISTS 40

NITRIC OXIDE 40

TABLE 15 PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE 41

DRUGS RELATED TO LIPID-DERIVED AUTACOIDS 41

EICOSANOID DRUGS 41

TABLE 16 EICOSANOID, EICOSANOID ANALOGS AND RECEPTOR AGONISTS/ANTAGONISTS 42

TABLE 16 (CONTINUED) 43

PLATELET-ACTIVATING FACTOR 43

TABLE 17 PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS 43

Chapter-5: REGULATORY ASPECTS

APPROVALS OF DRUGS RELATED TO AUTACOIDS 44

TABLE 18 NEW AND GENERIC DRUG APPROVALS OF THE DRUGS RELATED TO AUTACOIDS, 2006–2009 44

TABLE 18 (CONTINUED) 45

TABLE 18 (CONTINUED) 46

TABLE 18 (CONTINUED) 47

TABLE 18 (CONTINUED) 48

TABLE 19 NEW DRUG APPLICATIONS OF THE DRUGS RELATED TO AUTACOIDS 49

TABLE 19 (CONTINUED) 50

TABLE 20 SAFETY ALERTS, 2006-2009 50

Chapter-6: INDUSTRY STRUCTURE

MARKET LEADERS WITH THEIR PRODUCTS IN BIOGENIC AMINES 51

TABLE 21 LEADING MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS 51

TABLE 22 LEADING MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS 51

TABLE 23 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS 52

TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS 52

TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS 52

TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS 53

TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING SYMPATHOMIMETIC DRUGS 53

TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS 54

TABLE 29 LEADING MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS 54

TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS 54

MARKET LEADERS WITH THEIR PRODUCTS IN POLYPEPTIDE AUTACOIDS 55

TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS 55

TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 55

TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 56

MARKET LEADERS WITH THEIR PRODUCTS IN ENDOTHELIUM DERIVED AUTACOIDS 56

TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS 56

TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGS OF NITRIC OXIDE MARKET 56

MARKET LEADERS WITH THEIR PRODUCTS IN LIPID DERIVED AUTACOIDS 57

TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF EICOSANOIDS 57

TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS 57

MARKET SHARES OF INDUSTRY LEADERS 58

BIOGENIC AMINES 58

H1 Receptor Antagonists 58

TABLE 38 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%) 58

FIGURE 2 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%) 59

H2 Receptor Antagonists 59

TABLE 39 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%) 60

FIGURE 3 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%) 60

Serotonin Norepinephrine Reuptake Inhibitors 61

TABLE 40 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%) 61

FIGURE 4 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%) 61

Selective Serotonin Reuptake Inhibitors 62

TABLE 41 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2009 (%) 62

FIGURE 5 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2009 (%) 63

Serotonin Receptor Agonists Market 63

TABLE 42 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS, 2009 (%) 63

FIGURE 6 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS, 2009 (%) 64

Serotonin Receptor Antagonists Market 64

TABLE 43 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS, 2009 (%) 65

FIGURE 7 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS, 2009 (%) 65

Directly Acting Sympathomimetic Drugs 65

TABLE 44 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 66

FIGURE 8 DIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 66

Indirectly Acting Sympathomimetic Drugs 67

TABLE 45 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 67

FIGURE 9 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 68

Adrenolytics 68

TABLE 46 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%) 69

FIGURE 10 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%) 69

Dopamine Antagonists 70

TABLE 47 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%) 70

FIGURE 11 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%) 70

POLYPEPTIDE AUTACOIDS 71

Angiotensin II Receptor Antagonists 71

TABLE 48 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%) 71

FIGURE 12 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%) 72

Angiotensin-Converting Enzyme Inhibitors 72

TABLE 49 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2009 (%) 73

FIGURE 13 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2009 (%) 73

Drugs Related to Vasoactive Intestinal Polypeptides 74

TABLE 50 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%) 74

FIGURE 14 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%) 74

ENDOTHELIUM-DERIVED AUTACOIDS 75

Endothelin Receptor Antagonists 75

TABLE 51 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%) 75

FIGURE 15 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%) 75

Pharmaceutical Analogues of Nitric Oxide 76

TABLE 52 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%) 76

FIGURE 16 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%) 76

LIPID-DERIVED AUTACOIDS 77

Eicosanoids 77

TABLE 53 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%) 77

FIGURE 17 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%) 78

Platelet Activating Factor Receptor Antagonists 78

TABLE 54 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%) 78

FIGURE 18 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%) 79

Chapter-7: NEW DEVELOPMENTS

TABLE 55 NEW DEVELOPMENTS IN THE FIELD OF HISTAMINE ANTAGONISTS 80

TABLE 56 NEW DEVELOPMENTS IN THE FIELD OF SEROTONIN ANTAGONISTS 81

TABLE 56 (CONTINUED) 82

TABLE 56 (CONTINUED) 83

TABLE 57 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE AGONISTS 83

TABLE 58 NEW DEVELOPMENTS IN THE FIELD OF ADRENERGIC AGONISTS 84

TABLE 59 NEW DEVELOPMENTS IN THE FIELD OF ADRENOLYTICS 85

TABLE 59 (CONTINUED) 86

TABLE 60 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE ANTAGONISTS 87

TABLE 60 (CONTINUED) 88

TABLE 61 NEW DEVELOPMENTS IN THE FIELD OF ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS 88

TABLE 61 (CONTINUED) 89

TABLE 62 NEW DEVELOPMENTS IN THE FIELD OF VASOACTIVE INTESTINAL POLYPEPTIDE INHIBITORS 89

TABLE 62 (CONTINUED) 90

TABLE 63 NEW DEVELOPMENTS IN THE FIELD OF ENDOTHELIN ANTAGONISTS 90

TABLE 64 NEW DEVELOPMENTS IN THE FIELD OF EICOSANOIDS 91

TABLE 64 (CONTINUED) 92

Chapter-8: MARKET ANALYSIS

TABLE 65 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, THROUGH 2015 ($ BILLIONS) 93

FIGURE 19 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, 2008-2015 ($ BILLIONS) 94

MARKET SHARES OF AUTACOIDS MARKET, BY REGION 94

TABLE 66 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%) 95

FIGURE 20 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%) 95

DRUGS RELATED TO BIOGENIC AMINES 95

TABLE 67 WORLDWIDE MARKET FOR BIOGENIC AMINES, THROUGH 2015 ($ MILLIONS) 96

FIGURE 21 WORLDWIDE MARKET FOR BIOGENIC AMINES, 2008-2015 ($ MILLIONS) 96

HISTAMINES 97

TABLE 68 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, THROUGH 2015 ($ MILLIONS) 97

FIGURE 22 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, 2008-2015 ($ MILLIONS) 97

H1 and H2 Receptor Anatagonist 98

Market Overview 98

Market Revenue 98

TABLE 69 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 99

FIGURE 23 WORLDWIDE MARKET FOR H1 RECEPTOR ANATAGONISTS, 2008-2015 ($ MILLIONS 99

TABLE 70 WORLDWIDE MARKET FOR H2 RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 100

FIGURE 24 WORLDWIDE MARKET FOR H2 RECEPTOR ANATAGONISTS, 2008-2015 ($ MILLIONS) 100

SEROTONINS 101

TABLE 71 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, THROUGH 2015 ($ MILLIONS) 101

FIGURE 25 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, 2008-2015 ($ MILLIONS) 102

Serotonin Norepinephrine Reuptake Inhibitors 102

Market Overview 102

Market Revenue 103

TABLE 72 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, THROUGH 2015 ($ MILLIONS) 104

FIGURE 26 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2008-2015 ($ MILLIONS) 104

Serotonin Reuptake Inhibitors 105

Market Overview 105

Market Revenue 105

TABLE 73 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, THROUGH 2015 ($ MILLIONS) 106

FIGURE 27 WORLDWIDE MARKET FOR SEROTONIN REUPTAKE INHIBITORS, 2008-2015 ($ MILLIONS) 106

Serotonin Receptor Agonists 107

Market Overview 107

Market Revenue 107

TABLE 74 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, THROUGH 2015 ($ MILLIONS) 108

FIGURE 28 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, 2008-2015 ($ MILLIONS) 108

Serotonin Receptor Antagonists 109

Market Overview 109

Market Revenue 109

TABLE 75 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 110

FIGURE 29 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 110

CATECHOLAMINE DRUGS 110

TABLE 76 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, THROUGH 2015 ($ MILLIONS) 111

FIGURE 30 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, 2008- 2015 ($ MILLIONS) 111

Directly Acting Sympathomimetic Drugs 112

Market Overview 112

Market Revenue 112

TABLE 77 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 ($ MILLIONS) 113

FIGURE 31 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 ($ MILLIONS) 113

Indirectly Acting Sympathomimetic Drugs 114

Market Overview 114

Market Revenue 115

TABLE 78 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 ($ MILLIONS) 116

FIGURE 32 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 ($ MILLIONS) 116

Adrenolytics 117

Market Overview 117

Market Revenue 117

TABLE 79 WORLDWIDE MARKET FOR ADRENOLYTICS, THROUGH 2015 ($ MILLIONS) 118

FIGURE 33 WORLDWIDE MARKET FOR ADRENOLYTIC, 2008-2015 ($ MILLIONS) 118

Dopamine Antagonists 118

Market Overview 118

Market Revenue 119

TABLE 80 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 119

FIGURE 34 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, 2008-2015 ($ MILLIONS) 120

DRUGS RELATED TO POLYPEPTIDE AUTACOIDS 120

TABLE 81 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, THROUGH 2015 ($ MILLIONS) 121

FIGURE 35 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, 2008-2015 ($ MILLIONS) 121

ANGIOTENSIN DRUGS 122

TABLE 82 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, THROUGH 2015 ($ MILLIONS) 122

FIGURE 36 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, 2008-2015 ($ MILLIONS) 122

Angiotensin II Receptor Antagonists 123

Market Overview 123

Market Revenue 124

TABLE 83 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 124

FIGURE 37 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 124

Angiotensin-Converting Enzyme (ACE) Inhibitors 125

Market Overview 125

Market Revenue 125

TABLE 84 WORLDWIDE MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, THROUGH 2015 ($ MILLIONS) 126

FIGURE 38 WORLDWIDE MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2008-2015 ($ MILLIONS) 126

VASOACTIVE INTESTINAL POLYPEPTIDE 127

Market Overview 127

Market Revenue 127

TABLE 85 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, THROUGH 2015 ($ MILLIONS) 127

FIGURE 39 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2008-2015 ($ MILLIONS) 128

ENDOTHELIUM-DERIVED AUTACOIDS 128

TABLE 86 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, THROUGH 2015 ($ MILLIONS) 128

FIGURE 40 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2008-2015 ($ MILLIONS) 129

ENDOTHELIN RECEPTOR ANTAGONISTS 129

Market Overview 129

Market Revenue 130

TABLE 87 WORLDWIDE MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 130

FIGURE 41 WORLDWIDE MARKET FOR FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 131

NITRIC OXIDE 131

Market Revenue 131

TABLE 88 WORLDWIDE MARKET FOR NITRIC OXIDE, THROUGH 2015 ($ MILLIONS) 132

FIGURE 42 WORLDWIDE MARKET FOR FOR NITRIC OXIDE, 2008-2015 ($ MILLIONS) 132

DRUGS RELATED TO LIPID-DERIVED AUTACOIDS 132

TABLE 89 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, THROUGH 2015 ($ MILLIONS) 133

FIGURE 43 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, 2008-2015 ($ MILLIONS) 133

EICOSANOIDS 134

Market Overview 134

Market Revenue 134

TABLE 90 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, THROUGH 2015 ($ MILLIONS) 135

FIGURE 44 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, 2008-2015 ($ MILLIONS) 135

PLATELET-ACTIVATING FACTOR (PAF) RECEPTOR ANTAGONISTS 136

Market Overview 136

Market Revenue 136

TABLE 91 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 137

FIGURE 45 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 137

MARKET SHARES OF AUTACOIDS MARKET, BY TYPE 138

TABLE 92 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%) 138

FIGURE 46 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%) 138

Chapter-9: MARKET BY APPLICATIONS

MARKET SHARE OF APPLICATIONS 139

TABLE 93 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009 (%) 140

FIGURE 47 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009 140

RESPIRATORY DISEASES 140

MARKET REVENUE 141

TABLE 94 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, THROUGH 2015 ($ MILLIONS) 142

FIGURE 48 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, 2008-2015 ($ MILLIONS) 142

TABLE 95 SALES OF TOP-SELLING RESPIRATORY DRUGS, 2009 (%) 143

CARDIOVASCULAR DISEASES 143

MARKET REVENUE 143

TABLE 96 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, THROUGH 2015 ($ MILLIONS) 144

FIGURE 49 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, 2008-2015 ($ MILLIONS) 145

TABLE 97 SALES OF TOP-SELLING CARDIOVASCULAR DRUGS, 2009 (%) 145

CENTRAL NERVOUS SYSTEM DISEASES 146

MARKET REVENUE 146

TABLE 98 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM DISEASES, THROUGH 2015 ($ MILLIONS) 147

FIGURE 50 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM, 2008-2015 ($ MILLIONS) 147

TABLE 99 TOP-SELLING CENTRAL NERVOUS SYSTEM DRUGS IN THE ORDER OF SALES, 2009 148

GASTROINTESTINAL DISORDERS 148

MARKET REVENUE 148

TABLE 100 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 ($ MILLIONS) 149

FIGURE 51 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 ($ MILLIONS) 149

TABLE 101 TOP-SELLING GASTROINTESTINAL DRUGS IN THE ORDER OF THEIR SALES, 2009 150

ANTIEMETICS 150

MARKET REVENUE 150

TABLE 102 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 151

FIGURE 52 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 151

TABLE 103 TOP-SELLING ANTIEMETICS IN THE ORDER OF THEIR SALES, 2009 152

ANALGESICS 152

MARKET REVENUE 152

TABLE 104 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, THROUGH 2015 ($ MILLIONS) 153

FIGURE 53 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, 2008-2015 ($ MILLIONS) 153

OPHTHALMIC 154

MARKET REVENUE 154

TABLE 105 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, THROUGH 2015 ($ MILLIONS) 154

FIGURE 54 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, 2008-2015 ($ MILLIONS) 155

TABLE 106 TOP-SELLING OPHTHALMIC DRUGS IN THE ORDER OF SALES, 2009 155

OTHERS 156

MARKET REVENUE 156

TABLE 107 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 ($ MILLIONS) 156

FIGURE 55 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 ($ MILLIONS) 157

Chapter-10: PATENT ANALYSIS

PATENTS BY YEAR 158

TABLE 108 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006–2010 (FEB.) 159

FIGURE 56 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006–2010 (FEB.) 160

FIGURE 57 NUMBER OF PATENTS BY YEAR, 2006–2010 (FEB.) 160

FIGURE 57 (CONTINUED) 161

PATENTS BY TECHNOLOGY 161

TABLE 109 PATENTS BY TECHNOLOGY, 2006–2010 (FEB.) 161

FIGURE 58 PATENTS BY TECHNOLOGY, 2006–2010 (FEB.) 162

PATENTS BY TYPE 162

BIOGENIC AMINES 162

TABLE 110 PATENTS FOR BIOGENIC AMINES, 2006-2010 (FEB.) 162

FIGURE 59 PATENTS FOR BIOGENIC AMINES, 2006–2010 (FEB.) 163

POLYPEPTIDE AUTACOIDS 163

TABLE 111 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006-2010 (FEB.) 163

FIGURE 60 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006–2010 (FEB.) 164

LIPID-DERIVED AUTACOIDS 164

TABLE 112 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006–2010 (FEB.) 164

FIGURE 61 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006–2010 (FEB.) 165

ENDOTHELIUM-DERIVED AUTACOIDS 165

TABLE 113 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006-2010 (FEB.) 165

FIGURE 62 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006–2010 (FEB.) 166

PATENTS BY COMPANY 166

HISTAMINES 166

TABLE 114 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006–2010 (FEB.) 167

FIGURE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006–2010 (FEB.) 168

SEROTONINS 168

TABLE 115 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006–2010 (FEB.) 169

FIGURE 64 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006–20100 (FEB.) 169

CATECHOLAMINES 170

TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006–2010 (FEB.) 170

FIGURE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006–2010 (FEB.) 171

ACE INHIBITORS 171

TABLE 117 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006–2010 (FEB.) 171

FIGURE 66 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006–20100 (FEB.) 172

ANGIOTENSIN RECEPTOR BLOCKERS 172

TABLE 118 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–2010 (FEB.) 172

FIGURE 67 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–20100 (FEB.) 173

VASOACTIVE INTESTINAL POLYPEPTIDES 173

TABLE 119 NUMBER OF U.S. PATENTS BY COMPANY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.) 173

FIGURE 68 NUMBER OF U.S. PATENTS BY COMPANY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–20100 (FEB.) 174

PLATELET-ACTIVATING FACTOR INHIBITORS 174

TABLE 120 NUMBER OF U.S. PATENTS BY COMPANY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.) 174

EICOSANOIDS 174

TABLE 121 NUMBER OF U.S. PATENTS BY COMPANY FOR EICOSANOIDS, 2006–2010 (FEB.) 175

FIGURE 69 NUMBER OF U.S. PATENTS BY COMPANY FOR EICOSANOIDS, 2006–2010 (FEB.) 176

ENDOTHELIN RECEPTOR ANTAGONISTS 176

TABLE 122 NUMBER OF U.S. PATENTS BY COMPANY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.) 177

FIGURE 70 NUMBER OF U.S. PATENTS BY COMPANY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.) 177

PATENTS BY COUNTRY 177

HISTAMINES 177

TABLE 123 NUMBER OF U.S. PATENTS BY COUNTRY FOR HISTAMINES, 2006–2010 (FEB.) 178

FIGURE 71 NUMBER OF U.S. PATENTS BY COUNTRY FOR HISTAMINES, 2006–2010 (FEB.) 178

SEROTONINS 178

TABLE 124 NUMBER OF U.S. PATENTS BY COUNTRY FOR SEROTONINS, 2006–2010 (FEB.) 179

FIGURE 72 NUMBER OF U.S. PATENTS BY COUNTRY FOR SEROTONINS, 2006–2010 (FEB.) 179

CATECHOLAMINES 180

TABLE 125 NUMBER OF U.S. PATENTS BY COUNTRY FOR CATECHOLAMINES, 2006–2010 (FEB.) 180

FIGURE 73 NUMBER OF U.S. PATENTS BY COUNTRY FOR CATECHOLAMINES, 2006–2010 (FEB.) 181

ANGIOTENSIN II RECEPTOR BLOCKERS 181

TABLE 126 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANGIOTENSIN II RECEPTOR BLOCKERS, 2006–2010 (FEB.) 181

FIGURE 74 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANGIOTENSIN II RECEPTOR BLOCKERS, 2006–2010 (FEB.) 182

ACE INHIBITORS 182

TABLE 127 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE INHIBITORS, 2006–2010 (FEB.) 182

FIGURE 75 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE INHIBITORS, 2006–2010 (FEB.) 183

VASOACTIVE INTESTINAL POLYPEPTIDES 183

TABLE 128 NUMBER OF U.S. PATENTS BY COUNTRY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.) 183

FIGURE 76 NUMBER OF U.S. PATENTS BY COUNTRY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.) 184

PLATELET-ACTIVATING FACTOR INHIBITORS 184

TABLE 129 NUMBER OF U.S. PATENTS BY COUNTRY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.) 184

FIGURE 77 NUMBER OF U.S. PATENTS BY COUNTRY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.) 185

EICOSANOIDS 185

TABLE 130 NUMBER OF U.S. PATENTS BY COUNTRY FOR EICOSANOIDS, 2006–2010 (FEB.) 186

FIGURE 78 NUMBER OF U.S. PATENTS BY COUNTRY FOR EICOSANOIDS, 2006–2010 (FEB.) 186

ENDOTHELIN RECEPTOR ANTAGONISTS 187

TABLE 131 NUMBER OF U.S. PATENTS BY COUNTRY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.) 187

FIGURE 79 NUMBER OF U.S. PATENTS BY COUNTRY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.) 187

PATENTS BY ASSIGNEE 188

HISTAMINES 188

TABLE 132 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006–2010 (FEB.) 188

FIGURE 80 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006–2010 (FEB.) 188

SEROTONINS 189

TABLE 133 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006–2010 (FEB.) 189

FIGURE 81 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006–2010 (FEB.) 189

CATECHOLAMINES 190

TABLE 134 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006–2010 (FEB.) 190

FIGURE 82 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006–2010 (FEB.) 190

ACE INHIBITORS 191

TABLE 135 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006–2010 (FEB.) 191

FIGURE 83 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006–2010 (FEB.) 191

ANGIOTENSIN RECEPTOR BLOCKERS 192

TABLE 136 PATENTS BY ASSIGNEE FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–2010 (FEB.) 192

FIGURE 84 PATENTS BY ASSIGNEE FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–2010 (FEB.) 192

VASOACTIVE INTESTINAL POLYPEPTIDES 193

TABLE 137 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.) 193

FIGURE 85 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.) 193

PLATELET-ACTIVATING FACTOR INHIBITORS 194

TABLE 138 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.) 194

FIGURE 86 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.) 194

EICOSANOIDS 195

TABLE 139 PATENTS BY ASSIGNEE FOR EICOSANOIDS, 2006–2010 (FEB.) 195

FIGURE 87 PATENTS BY ASSIGNEE FOR EICASANOIDS, 2006–2010 (FEB.) 195

ENDOTHELIN RECEPTOR ANTAGONISTS 196

TABLE 140 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006–2010 (FEB.) 196

FIGURE 88 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006–2010 (FEB.) 196

Chapter-11: CURRENT SITUATION OF AUTACOID-RELATED DRUGS

FACTS ABOUT AUTACOID-RELATED DRUGS 197

FACTORS AFFECTING THE SALES OF AUTACOID-RELATED DRUGS 198

COMPETITION 198

COST 198

PATENT EXPIRATIONS 199

TABLE 141 PATENT EXPIRATIONS 200

MAJOR FACTORS FOR FUTURE GROWTH 200

LIFE EXPECTANCY 200

PATENT PROTECTION 201

DRUGS PORTFOLIO MANAGEMENT 201

STRATEGIES OF PHARMACEUTICAL COMPANIES 201

PATENT EXTENSIONS 201

MERGERS, ACQUISITIONS AND COLLABORATIONS 202

PRESCRIPTION TO OVER-THE-COUNTER SWITCHING 202

DIRECT-TO-CONSUMER ADVERTISING 203

APPEAL FOR GENERIC DRUG MANUFACTURING 203

Chapter-12: COMPANY PROFILES

ABBOTT LABORATORIES 204

ACTELION PHARMACEUTICALS LTD. 204

ALCON INC. 205

ALLERGAN INC. 206

APOTEX 206

APP PHARMA 207

ASTRAZENECA PLC 208

AUROBINDO PHARMA 209

BAXTER INTERNATIONAL INC. 209

BAYER HEALTHCARE 210

BEDFORD LABORATORIES 210

BIOVAIL CORPORATION 210

BOEHRINGER INGELHEIM 211

BRISTOL-MYERS SQUIBB 212

CHATTEM INC. 212

CIPLA LTD. 213

CYPRESS BIOSCIENCE, INC. 213

DAIICHI SANKYO CO. LTD. 214

DAVA PHARMCEUTICALS INC. 214

DEY PHARMA, L.P. 215

DR. REDDY'S LABORATORIES LIMITED 215

ELI LILLY & CO. 216

FOREST LABORATORIES INC. 217

GILEAD SCIENCES INC. 217

GLAXO SMITH KLINE PLC 218

HELSINN HEALTHCARE S.A. 219

HOSPIRA INC. 220

IPSEN S.A. 220

JAZZ PHARMACEUTICALS INC. 221

JOHNSON & JOHNSON 222

KING PHARMACEUTICALS INC. 222

MERCK & CO. INC. 223

MYLAN LABS 224

NOVARTIS AG 225

NUVO RESEARCH INC. 226

NYCOMED US INC. 226

PAR PHARMACEUTICAL COMPANIES INC. 227

PEDINOL PHARMACAL, INC. 228

PERRIGO COMPANY 228

PFIZER INC. 229

PROSTRAKAN GROUP PLC 229

ROCHE 230

SALIX PHARMACEUTICALS 231

SANDOZ 231

SANOFI- AVENTIS 232

SHIONOGI PHARMA INC. 233

SHIRE PLC 233

SOLVAY PHARMACEUTICALS SA 234

TARO PHARMACEUTICAL INDUSTRIES LTD. 234

TEVA PHARMACEUTICAL INDUSTRIES LIMITED 235

UCB INC. 235

UNITED THERAPEUTICS 236

VALEANT PHARMACEUTICALS INTERNATIONAL 236

VIVUS INC. 236

WATSON PHARMACEUTICALS 237

XANODYNE 238

ZYDUS PHARMA USA 238

APPENDIX I—ABBREVIATIONS AND DEFINITIONS 239

ABBREVIATIONS AND DEFINITIONS 239

ABBREVIATIONS AND DEFINITIONS (CONTINUED) 240

To order this report:

Drug and Medication Industry: Autacoids and Related Drugs: Technologies and Global Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker